Overview

Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Treatments:
Bevacizumab
Endothelial Growth Factors
Sunitinib